Partnerships

Partnerships

We enjoy working with like-minded partners who want to join forces to improve the lives of patients living with cancer and other diseases.

Incyte is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can affect patients’ lives. We recognize that we do not have a monopoly on good ideas and innovative approaches to therapy. We are committed to alliances, partnerships, and collaborations and will opportunistically evaluate assets that have the potential to expand our pipeline, geographic reach, or technological base. To contact our Business Development team, please send an e-mail to bd@incyte.com.

LICENSING AGREEMENTS

Eli Lilly and Company

In December 2009, we entered into a License, Development, and Commercialization Agreement with Lilly. Under the terms of the agreement, Lilly received exclusive worldwide development and commercialization rights to our JAK inhibitor baricitinib and certain back-up compounds for inflammatory and autoimmune diseases.

Novartis International Pharmaceutical Ltd.

In November 2009, we entered into a Collaboration and License Agreement with Novartis. Under the terms of the agreement, Novartis received exclusive development and commercialization rights outside of the United States to our JAK inhibitor ruxolitinib and certain back-up compounds for hematologic and oncology indications. We retained exclusive development and commercialization rights to Jakafi® (ruxolitinib) in the United States. Novartis also received worldwide exclusive development and commercialization rights to our c-MET inhibitor compound capmatinib and certain back-up compounds in all indications. We retained options to co-develop and to co-promote capmatinib in the United States.

In April 2016, Incyte and Novartis also agreed to amend their Collaboration and License Agreement, granting Novartis the rights to research, develop, and commercialize ruxolitinib for GVHD outside the United States.

Agenus Inc.

In 2015, we announced a global license, development, and commercialization agreement with Agenus Inc. focused on novel immuno-therapeutics using Agenus Inc.’s proprietary Retrocyte Display antibody discovery platform. The alliance will initially focus on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3, and TIM-3.

ARIAD Pharmaceuticals, Inc.

In May 2016, we entered into a Share Purchase Agreement with ARIAD Pharmaceuticals, Inc. pursuant to which we acquired ARIAD’s European subsidiaries responsible for the commercialization of Iclusig® (ponatinib) in the European Union and 22 other countries. In addition, we entered into a License Agreement granting Incyte an exclusive license to develop and commercialize Iclusig in Europe.

Merus N.V.

In 2016, we announced a global, strategic collaboration and license agreement with Merus N.V. focused on the research, discovery, and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The agreement grants Incyte exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs.

Calithera Biosciences, Inc.

In 2017, we announced a global collaboration and license agreement with Calithera Biosciences, Inc. for the research, development, and commercialization of CB-1158, a first-in-class, small-molecule arginase inhibitor, in hematology and oncology.

Macrogenics, Inc.

In 2017, we announced an exclusive global collaboration and license agreement with MacroGenics, Inc. for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).